The IPKat

AUGUST 13, 2024

Upcoming events Assimilate IP Autumn Courses and Webinars : Protecting Confidential Information, Trade Secrets and Know How : 11 September 2024 Freedom to Operate for Life Sciences and Pharma : 25 & 26 September 2024 Patent and Know How Licensing : 9 & 10 October 2024 IP Essentials – Patent or Trade Secret? Details here.

Intellectual Property 62

Intellectual Property IP Journalism Confidentiality 62

LexBlog IP

AUGUST 16, 2023

In February 2023, Formycon announced its entry into a global license agreement with Fresenius Kabi to commercialize FYB202 in key global markets after successful regulatory approvals. According to the press release, Formycon plans to submit a biologics license application later in 2023 to seek regulatory approval for FBY202.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

LexBlog IP

AUGUST 30, 2023

market on March 7, 2025, if approved by FDA. J&J also recently filed a confidential settlement and license agreement to terminate a Samsung Bioepis challenge to all claims of U.S.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

SpicyIP

APRIL 30, 2023

Nirtech – Analysing the Claim of Breach of Confidential Information Image from here. Ex-employees using confidential information acquired from the former employer! Nirtech on protecting confidential information. Other posts Rochem v. In this post, the author discusses the Bombay High Court order in Rochem v.

Confidentiality 105

Confidentiality Trademark Copyright Patent 105

The IPKat

NOVEMBER 14, 2022

a wise cat that care about environment kindly provided in CC0 Public Domain license by Pixhere.com) Having to make a selection among the many topics covered, this GuestKat finds it interesting to note that during the conference the EPO case G2/21 on 'plausibility', was repeatedly discussed from different angles.

IP 76

IP Marketing Marketing Confidentiality 76

LexBlog IP

JANUARY 16, 2023

The European Commission expressed its hope that the provisions of the regulation will enter into force across all EU member states in 2025. If approved, the EHDS proposal would introduce a new regime for the compulsory licensing of health data to third parties.

Intellectual Property 52

Intellectual Property Confidentiality Business Advertising 52